Insiders bought recently before the offering at $1.10 per share. Slightly risky when Actimab-A Phase 2 results could come out anytime.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
